Why the study?
The study was conducted to evaluate the outcomes of recent randomized controlled trials involving siRNA treatments aimed at lowering Lp(a) levels, a known cardiovascular risk factor.
Do siRNA therapies reduce Lp(a) levels?
Do siRNA therapies reduce Lp(a) levels?
siRNA therapies effectively lower Lp(a), LDL-c, and apolipoprotein B levels with mild injection site reactions.
Answers are grounded in this paper and cite their sources.
siRNA therapies effectively lower Lp(a) with minimal adverse effects; extends RCT evidence but leaves cardiovascular outcomes open.
BACKGROUND: This systematic review investigates the effect of small interfering RNA (siRNA) therapies on lipoprotein(a) [Lp(a)] levels. The purpose is to evaluate the outcomes of recent randomized controlled trials (RCTs) involving siRNA treatments aimed at lowering Lp(a) levels, a known cardiovascular risk factor. METHODS: A comprehensive search across multiple databases was conducted, identifying 20 published and ongoing RCTs that examined the effects of siRNA therapies such as inclisiran, olpasiran, and SLN360 on Lp(a) levels. The included studies were analyzed to assess Lp(a) reductions and other lipid-related outcomes. RESULTS: The RCTs demonstrated significant reductions in Lp(a) levels following siRNA therapy. Additional reductions were noted in LDL-c and apolipoprotein B levels. Side effects were typically mild, including injection site reactions. CONCLUSIONS: siRNA therapies show promise in effectively lowering Lp(a) levels, with minimal adverse effects. However, further research is required to establish their long-term safety and efficacy.
No takes yet. Share an insight, caveat, or question.
Almaadawy et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: